Table 16:

Recommendation for vadadustat as an alternative to ESA for anemia in NDD-CKD patients

Recommendation for use in research setting only	This recommendation is evidence informed.
Vadadustat should not be used for NDD-CKD patients, except in the context of an approved randomized controlled trial. The panel recommends conduct of large head-to-head multicentric randomized controlled trials in the South Asian region on NDD-CKD patients and measuring critically important outcomes (as elucidated in this guideline) such that evidence base for vadadustat is improved.

ESA: Eythropoiesis-stimulating agents, NDD: Nondialysis dependent, CKD: Chronic kidney disease